Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will focus on two new, ready-to-market automated options for cervical cancer screening at the International Papillomavirus Conference & Clinical Workshop (IPV) September 17th through 22nd in Berlin, Germany.
Hologic's ThinPrep 5000 STS (Sample Transfer System) and Cervista MTA (Medium Throughput Automation) system will be featured in the Hologic exhibit. When the Cervista MTA system is combined with the ThinPrep 5000 sample transfer system, small-to-mid-sized laboratories have a scalable, fully-automated solution for Human Papillomavirus (HPV) testing. Small-to-mid-sized laboratories typically run less than 12,000 HPV tests/year. HPV is one of the most common sexually transmitted diseases and is recognized as the cause of most cervical cancers. By eliminating what is often a manual system involving time and multiple handling of the samples, the combined systems are designed to give laboratories an enhanced chain-of-custody procedure allowing for even more confidence in their patient results.
"Our new automated Cervista and ThinPrep systems represent a tremendous opportunity for our laboratory partners in markets recognizing the CE mark," said Rohan Hastie, Vice President and General Manager, Hologic Molecular Diagnostics. "These products are designed to provide the small and medium volume laboratory access to the most effective and efficient cervical cancer screening technology available, while allowing them the flexibility to address their specific productivity and throughput needs."
Hologic is sponsoring the "HPV-Testing out of the ThinPrep PreservCyt Vial: Customer Experiences and Automation Solutions" symposium on Monday September 19th from 17.30 to 18.30 at the IPV meeting. The symposium is open to anyone attending the conference. Over 1,000 conference attendees are expected to attend.
Research on human papillomaviruses has made impressive progress in recent years. Better diagnosis and therapies have helped to significantly reduce the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV. However, next to breast cancer, cervical carcinoma remains the second most frequent cancer affecting women worldwide. The IPV meeting and workshop is the major international conference that encompasses all aspects of HPV research. Hologic is a gold sponsor of the event.
SOURCE Hologic, Inc.